Bulk Pharmaceutical API Sources for dolutegravir sodium

Bulk Pharmaceutical API Sources for dolutegravir sodium

Vendor	Vendor Homepage	Vendor Sku	API Url
Sun-shine Chemical		GSK1349572A
MedChemexpress MCE		HY-13238A
AKos Consulting & Solutions		AKOS025396662
AbaChemScene		CS-3496
TargetMol		T2329
MolPort		MolPort-039-136-625
ApexBio Technology		B5856

Dolutegravir Sodium API Sourcing Landscape

Last updated: February 19, 2026

What is Dolutegravir Sodium and Why is it a Critical API?

Dolutegravir sodium is the active pharmaceutical ingredient (API) in Tivicay and is also a component of the combination antiretroviral therapies Triumeq and Juluca. It is an integrase strand transfer inhibitor (INSTI) used in the treatment of human immunodeficiency virus type 1 (HIV-1) infection. The drug's efficacy and favorable safety profile have established it as a preferred component in various HIV treatment regimens globally. This demand translates into a consistent need for reliable and cost-effective sources of high-quality dolutegravir sodium API.

Key Global Manufacturers of Dolutegravir Sodium API

The manufacturing of dolutegravir sodium API is concentrated among a select group of global pharmaceutical ingredient producers. These manufacturers vary in scale, regulatory compliance, and geographical location, influencing supply chain dynamics and pricing.

• Viatris Inc. (formerly Mylan N.V.): A significant player, Viatris produces dolutegravir sodium API through its contract manufacturing organizations (CMOs). The company has been a key supplier to various generic drug manufacturers and has also been involved in voluntary licensing programs to increase access in low- and middle-income countries.
• Indian Pharmaceutical Manufacturers: India is a primary hub for API production due to its strong manufacturing infrastructure, skilled workforce, and cost advantages. Several Indian companies are approved by regulatory bodies like the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) for API manufacturing.
  • Divi's Laboratories Limited: A large-scale producer of APIs and intermediates, Divi's is known for its robust manufacturing capabilities and strong regulatory track record.
  • Laurus Labs Limited: This company is a significant manufacturer of APIs, including antiretrovirals. Laurus Labs has invested heavily in research and development and has a strong presence in regulated markets.
  • Hetero Drugs Ltd.: A leading generic pharmaceutical company, Hetero is involved in the manufacturing of various APIs, including those for HIV treatment.
  • Dr. Reddy's Laboratories Ltd.: Another major Indian pharmaceutical company with a substantial API manufacturing division, Dr. Reddy's is a key supplier in global markets.
• Chinese Pharmaceutical Manufacturers: China is another critical global supplier of APIs. While specific company names often operate under strict confidentiality agreements for finished drug product manufacturers, numerous Chinese CMOs and API producers are engaged in the synthesis of dolutegravir sodium. These entities often compete on price and volume.

Regulatory Landscape and Quality Standards

The production of dolutegravir sodium API is subject to stringent regulatory oversight to ensure product safety, efficacy, and quality. Key regulatory bodies and their requirements are critical for sourcing decisions.

• U.S. Food and Drug Administration (FDA): The FDA requires API manufacturers to comply with Current Good Manufacturing Practices (cGMP). Facilities are subject to inspection, and API batches must meet predefined specifications for purity, potency, and impurity profiles. Drug Master Files (DMFs) are submitted to the FDA, detailing the manufacturing process, controls, and specifications of the API.
• European Medicines Agency (EMA): Similar to the FDA, the EMA mandates cGMP compliance. Active Substance Master Files (ASMFs) are used in Europe to provide confidential detailed information about the manufacturing of an API.
• World Health Organization (WHO): The WHO Prequalification Programme assesses the quality, safety, and efficacy of medicines, including APIs, for procurement by UN agencies and eligible countries. Manufacturers seeking WHO prequalification must meet stringent WHO GMP standards.
• Other National Regulatory Authorities: Agencies in countries like Japan (PMDA), Canada (Health Canada), and Australia (TGA) also have their own approval processes and cGMP requirements.

Key Quality Attributes for Dolutegravir Sodium API:

• Purity: Typically, purity specifications are set at >99.0%, with limits on individual impurities and total impurities.
• Impurity Profiling: Identifying and quantifying process-related impurities and degradation products is crucial. Specific limits are set for known and unknown impurities.
• Physical Characteristics: Particle size distribution, polymorphic form, and bulk density can impact downstream processing and final drug product formulation.
• Residual Solvents: Limits for residual solvents, as defined by ICH Q3C guidelines, must be met.
• Heavy Metals: Compliance with limits for heavy metals is mandatory.

Supply Chain Dynamics and Risk Factors

The global supply chain for dolutegravir sodium API is characterized by several factors influencing availability, pricing, and potential disruptions.

Factors Affecting Supply and Pricing

• Manufacturing Capacity: The aggregate global manufacturing capacity versus current and projected demand. Oversupply can lead to price erosion, while undersupply can drive up costs.
• Raw Material Availability and Cost: The accessibility and cost of key starting materials and intermediates used in the synthesis of dolutegravir sodium. Geopolitical events, environmental regulations, or disruptions in upstream supply can impact costs.
• Regulatory Hurdles: Delays in regulatory approvals for new manufacturers or manufacturing site changes can impact supply.
• Intellectual Property: While the primary patents for dolutegravir have expired in many regions, patents related to specific polymorphs, manufacturing processes, or formulations can still influence market dynamics.
• Voluntary Licensing and Access Programs: Agreements by the originator (ViiV Healthcare) with the Medicines Patent Pool and other entities allow for the production of dolutegravir by generic manufacturers in low- and middle-income countries. This increases overall API production volume but can fragment the market.

Potential Supply Chain Risks

• Geopolitical Instability: Reliance on specific regions for API manufacturing can expose the supply chain to risks associated with political unrest, trade wars, or export restrictions.
• Environmental Regulations: Increasingly stringent environmental regulations in manufacturing hubs like China and India can lead to temporary plant shutdowns or increased compliance costs, impacting production volumes and prices.
• Quality Control Failures: Batch rejections due to quality deviations or findings during regulatory inspections can lead to significant supply shortages.
• Logistics and Transportation: Global supply chains are vulnerable to disruptions in shipping, port congestion, or increased freight costs.
• Cybersecurity Threats: Digital supply chain management systems are susceptible to cyberattacks that could disrupt operations or compromise sensitive data.
• Single-Source Dependencies: Over-reliance on a single manufacturer or a limited number of manufacturers for API can create significant vulnerability. Diversification of suppliers is a critical risk mitigation strategy.

Sourcing Strategies for Dolutegravir Sodium API

Procuring dolutegravir sodium API requires a strategic approach that balances cost, quality, reliability, and regulatory compliance.

Key Considerations for Sourcing

1. Regulatory Compliance:

   • Verify the manufacturer's regulatory filings (e.g., DMF, ASMF) and their acceptance by target market regulatory authorities (FDA, EMA, etc.).
   • Request Certificates of Analysis (CoA) for each batch, detailing compliance with agreed-upon specifications.
   • Assess the manufacturer's audit history and cGMP compliance. Site audits are essential for critical suppliers.

2. Quality Assurance:

   • Establish robust quality agreements with API suppliers.
   • Define clear specifications for purity, impurity profiles, physical properties, and other critical quality attributes.
   • Implement a program for trending API quality data.

3. Supply Chain Reliability and Capacity:

   • Assess the manufacturer's production capacity and track record of meeting delivery timelines.
   • Evaluate the manufacturer's business continuity plans and risk mitigation strategies.
   • Consider second-sourcing or multi-sourcing strategies to mitigate reliance on a single supplier.

4. Cost and Commercial Terms:

   • Obtain competitive quotes from multiple qualified suppliers.
   • Negotiate clear payment terms, lead times, and Incoterms.
   • Understand the impact of raw material price fluctuations on API pricing.

5. Technical Support and Collaboration:

   • Ensure the API supplier can provide comprehensive technical support, including process chemistry insights and troubleshooting assistance.
   • Foster a collaborative relationship for continuous improvement and problem-solving.

Data Points for Supplier Evaluation

Metric	Typical Requirement/Consideration	Data Source Examples
Regulatory Approvals	FDA DMF, EMA ASMF, WHO PQ listing	Regulatory agency databases, manufacturer website, direct inquiry
cGMP Compliance	Recent successful FDA/EMA inspections, absence of significant observations (e.g., Form 483, Warning Letters)	Inspection reports (publicly available), audit reports
Annual Production Capacity	Sufficient to meet projected demand (e.g., multi-ton capacity)	Manufacturer disclosures, supply chain assessments
Lead Time	3-6 months typical for custom orders, shorter for established supply	Supplier quotations, past performance data
Impurity Profile	Compliance with ICH guidelines, specific limits for known and unknown impurities	CoA, DMF/ASMF
Batch Consistency	Low variability in key quality attributes across multiple batches	Historical CoA data, quality trending reports
Financial Stability	Long-term operational viability, creditworthiness	Dun & Bradstreet reports, financial statements (if public)
Geographic Diversification	Manufacturing sites in multiple regions to mitigate regional risks	Manufacturer disclosures
Quality Agreement Status	Executed and robust quality agreement in place	Legal department review
IP Landscape	No active IP challenges or litigation impacting production or sale	Legal counsel review, patent searches

Key Takeaways

The global supply of dolutegravir sodium API is robust, driven by established pharmaceutical manufacturers in India, China, and by Viatris. Sourcing decisions must prioritize stringent regulatory compliance (FDA, EMA, WHO cGMP), verified through DMF/ASMF submissions and successful site audits. Quality assurance, including comprehensive impurity profiling and batch consistency, is paramount. Supply chain reliability is enhanced through assessing manufacturing capacity, lead times, and implementing multi-sourcing strategies to mitigate risks such as geopolitical instability and regulatory changes. Cost negotiation must be balanced against the assurance of consistent quality and supply.

Frequently Asked Questions

1. What is the primary difference in quality standards for API supplied to regulated markets versus emerging markets? Regulated markets (e.g., U.S., EU) demand strict adherence to ICH guidelines and cGMP, often requiring FDA/EMA approved DMFs. Emerging markets may accept WHO prequalified APIs or those meeting national pharmacopoeial standards, which can sometimes have less stringent impurity controls or analytical methods.

2. How can a pharmaceutical company best diversify its dolutegravir sodium API supply chain? Diversification involves identifying and qualifying at least two manufacturers in different geographic regions (e.g., one in India and one in China, or a U.S./EU-based CMO if cost-effective). This requires parallel regulatory filings and robust quality agreements with each.

3. What is the typical lead time for a new supplier to become qualified and begin delivering dolutegravir sodium API? The qualification process, including site audits, quality agreement finalization, and initial batch testing, can take 6-12 months. If a new DMF/ASMF filing is required or the manufacturer is not yet approved by the target regulatory authority, this timeline can extend significantly.

4. Are there significant patent barriers to sourcing generic dolutegravir sodium API? The core patents for dolutegravir sodium have expired in many key markets, facilitating generic competition. However, patents related to specific crystalline forms (polymorphs), manufacturing processes, or combination therapies may still exist and require careful legal review before generic API production.

5. How does the Medicines Patent Pool (MPP) agreement impact the global supply and pricing of dolutegravir sodium API? The MPP agreement allows licensed generic manufacturers in low- and middle-income countries to produce and distribute dolutegravir. This significantly increases global supply volume and drives down API costs in these regions, contributing to broader access but also creating price differentiation between markets.

Citations

[1] ViiV Healthcare. (n.d.). Tivicay Prescribing Information. U.S. Food & Drug Administration. [2] ViiV Healthcare. (n.d.). Triumeq Prescribing Information. U.S. Food & Drug Administration. [3] ViiV Healthcare. (n.d.). Juluca Prescribing Information. U.S. Food & Drug Administration. [4] U.S. Food & Drug Administration. (n.d.). Drug Master Files. Retrieved from [FDA Website URL - Actual URL needs to be inserted if publicly available] [5] European Medicines Agency. (n.d.). Active Substance Master File (ASMF). Retrieved from [EMA Website URL - Actual URL needs to be inserted if publicly available] [6] World Health Organization. (n.d.). WHO Prequalification Programme. Retrieved from [WHO Website URL - Actual URL needs to be inserted if publicly available] [7] International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. (2023). ICH Harmonised Tripartite Guideline Impurities: Guideline for Residual Solvents Q3C(R8).